Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jun 20;63(6):2400160.
doi: 10.1183/13993003.00160-2024. Print 2024 Jun.

Clinical remission with biologic therapies in severe asthma: a matter of definition

UK Severe Asthma Registry; P Jane McDowell  1   2 , Ron McDowell  3 , John Busby  3 , M Chad Eastwood  1   2 , Pujan H Patel  4 , David J Jackson  5 , Adel Mansur  6 , Mitesh Patel  7 , Hassan Burhan  8 , Simon Doe  9 , Rekha Chaudhuri  10 , Robin Gore  11 , James W Dodd  12 , Deepak Subramanian  13 , Thomas Brown  14 , Liam G Heaney  15   2
Affiliations
Comment

Clinical remission with biologic therapies in severe asthma: a matter of definition

UK Severe Asthma Registry et al. Eur Respir J. .

Abstract

There is currently no evidence to support the use of maintenance and reliever therapy (MART) in patients with severe asthma and persistently elevated T2 biomarkers despite adherence to high dose ICS treatment https://bit.ly/42IOVbA

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The UK Severe Asthma Registry (UKSAR) does not receive any monetary benefits or benefits-in-kind from any pharmaceutical entity; UKSAR does make limited data contributions to the International Severe Asthma Registry (ISAR) and the ERS clinical research collaborative (SHARP), which do receive pharmaceutical funding. P.J. McDowell reports speaker fees from GSK, and support to attend scientific meetings from Chiesi. J. Busby reports grants from AstraZeneca, and personal fees from Nuvoair. M.C. Eastwood reports support to attend meetings from GSK. P.H. Patel has received advisory board fees and lecture fees from AstraZeneca, GlaxoSmithKline, Novartis and Sanofi. D.J. Jackson has received speaker fees and consultancy fees from AZ, GSK and Sanofi Regeneron. A. Mansur declares personal and to-institution payments for talks, advisory board meetings and sponsorship to attend conferences from AZ, GSK, Teva, Sanofi, Novartis and BI, and also declares research grants from GSK. H. Burhan reports fees for advisory board meetings from AstraZeneca and Novartis, honoraria for lectures from AstraZeneca, Chiesi, GSK and Sanofi, and support for attending conferences from AstraZeneca, Chiesi and GSK. S. Doe reports fees for advisory boards from Vertex, Gilead and Novartis, support for attending congresses from GSK, AZ, Gilead, Teva, Sanofi, Chiesi and Forest, and lecture fees from GSK, AZ and Sanofi. R. Chaudhuri has received lecture fees from GSK, AZ, Teva, Chiesi, Sanofi and Novartis, honoraria for advisory board meetings from GSK and AZ, sponsorship to attend international scientific meetings from Chiesi, Sanofi and GSK, and a research grant (paid to institute) from AZ for a UK multicentre study. R. Gore has received fees for lecturing from AZ, Novartis, Sanofi and GSK. J.W. Dodd has received honoraria for participating on advisory boards and given lectures at meetings supported by GSK, Boehringer Ingelheim, Chiesi, AstraZeneca, Fisher & Paykel and Aerogen, received sponsorship for attending international scientific meetings from Chiesi, and has also taken part in asthma clinical trials sponsored by Sanofi, AstraZeneca and Chiesi for which his institution received remuneration; his institution has received funding for research from MRC, NIHR, SBRI, NHSx, Templeton Foundation and Southmead Hospital research charity. D. Subramanian is part of the AZ Precision National Working Group and has received speaker fees from Chiesi. T. Brown has received fees as an external expert from AstraZeneca, speaker fees from AstraZeneca, GlaxoSmithKline, Sanofi, Teva, Novartis and Chiesi, honoraria for advisory board attendance from AstraZeneca, Sanofi and Teva, and sponsorship to attend international scientific meetings from Sanofi, GSK, Teva, Chiesi and Napp Pharmaceuticals. L.G. Heaney is academic lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma, which involves industrial partnerships with a number of pharmaceutical companies. The remaining authors have no potential conflicts of interest to disclose.

Comment on

References

    1. Beasley R, Noble J, Weatherall M. Clinical remission with biologic therapies in severe asthma: a matter of definition. Eur Respir J 2023; 62: 2301844. doi:10.1183/13993003.01844-2023 - DOI - PubMed
    1. Rogliani P, Ritondo BL, Ora J, et al. . SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. Eur Respir J 2020; 56: 2000625. doi:10.1183/13993003.00625-2020 - DOI - PubMed
    1. Beasley R, Harrison T, Peterson S, et al. . Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma: a systematic review and meta-analysis. JAMA Netw Open 2022; 5: e220615. doi:10.1001/jamanetworkopen.2022.0615 - DOI - PMC - PubMed
    1. McDowell PJ, McDowell R, Busby J, et al. . Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J 2023; 62: 2300819. doi:10.1183/13993003.00819-2023 - DOI - PMC - PubMed
    1. Pavord ID, Jeffery PK, Qiu Y, et al. . Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. J Allergy Clin Immunol 2009; 123: 1083–1089.e1-7. doi:10.1016/j.jaci.2009.02.034 - DOI - PubMed